Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Randomized, Placebo-controlled, Double-blind, Parallel-group, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

Main Inclusion Criteria:

• Patient meets DSM-IV criteria for schizophrenia.
• Patient is 18 or older but younger than 75 years of age on the day of signing informed consent.
• Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent.

Main Exclusion Criteria:

• Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
• Patient has Parkinson's disease.
• Patient has a history or complication of malignancy.